Shanghai Adrenal Disease Cohort
Official title: Shanghai Clinical Cohort - Adrenal Disease
Run by Shanghai Jiao Tong University School of Medicine · NCT07191951 · Data updated 2026-11-12
This project enrolls adults with adrenal diseases to collect clinical, imaging, and lab data and samples to see if better tests, diagnoses, and treatments can be developed.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Shanghai Jiao Tong University School of Medicine Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | July 25, 2025 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | November 17, 2025 |
| Trial ID | NCT07191951 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with a confirmed adrenal diagnosis (e.g., aldosteronism, Cushing's syndrome, pheochromocytoma, adrenocortical carcinoma, or congenital adrenal hyperplasia) who can give informed consent and comply with study procedures.
✕Probably not a fit
People without adrenal disease, those outside the 18–75 age range, those unwilling to consent, or patients with medical or psychological conditions that preclude participation are unlikely to receive direct benefit from this cohort.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort will enroll adults (18–75) diagnosed with adrenal conditions such as primary aldosteronism, Cushing's syndrome, pheochromocytoma, adrenocortical carcinoma, and congenital adrenal hyperplasia. Participants will receive standard-of-care treatment (surgery, radiotherapy, and/or medications) while researchers collect hormone assays, imaging, pathology, and molecular data and track clinical outcomes over time. The study aims to address variability in hormone testing, improve localization on imaging, clarify tumor molecular features, and identify prognostic markers from integrated datasets. Results are intended to inform subtype definitions, diagnostic criteria, and more personalized prevention and treatment strategies for adrenal diseases.
Why it matters
Potential benefit: If successful, the cohort could enable more accurate diagnoses, clearer tumor characterization, and more personalized treatment choices that improve patient outcomes.
How similar studies have gone: Prior observational and molecular studies of specific adrenal conditions have produced useful subtype and diagnostic insights, but comprehensive integrated cohorts combining clinical, imaging, and molecular data across adrenal diseases are still relatively limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * A signed and dated informed consent form * Commitment to abide by the study procedures and cooperate with the implementation of the entire study process * Patients diagnosed with adrenal diseases, including aldosteronism, Cushing's syndrome, pheochromocytoma, adrenocortical carcinoma, and congenital adrenal hyperplasia; regardless of whether they have received adrenal surgery, radiotherapy, and/or medication therapy * Aged between 18 and 75 years Exclusion Criteria: * Subjects meeting any of the following criteria will be excluded from this study: * Refuse to sign the informed consent form * Patients without adrenal diseases * Have specified diseases or conditions (physical or psychological, identified through physical examination) that warrant exclusion from the study
Where it's running
-
Jiang yiran
Shanghai, China Recruiting
Study contacts
- Study coordinator: Yiran Jiang
- Email: jyr11662@rjh.com.cn
- Phone: 0086-021-64370045
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
FM Move: A New Method for Moving Back Teeth During Clear Aligner Therapy
A single-group study tests a new FM method to move the canine and first molar together in people needing back-teeth movement, to see if treatment time can be shortened.
-
Sitogilun Malate with Amlodipine in High Blood Pressure with Early Kidney Risk
This trial tests whether sitogilun malate plus amlodipine helps lower blood pressure in adults with mild-to-moderate hypertension and early signs of kidney stress.
-
Active safety and performance monitoring of a biodegradable PFO closure device and a transcatheter mitral valve repair system
This study tracks how well a biodegradable PFO closure device and a transcatheter mitral valve repair system work and stay safe when used in routine care.
-
AI-powered personalized exercise coaching for women with breast cancer
This trial tests whether an AI-driven, personalized exercise program helps women with breast cancer after treatment compared to standard exercise guidance.
-
Oral health, saliva bacteria, and disease activity in children with JIA
This study checks if how active juvenile idiopathic arthritis is relates to oral health in children who already receive rheumatology care.
-
Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer
This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.